Hyderabad, June 13, 2025: Sigachi Industries Ltd., India’s largest
producer of Microcrystalline Cellulose (MCC), continues to set new benchmarks
in global pharmaceutical excipients while strategically expanding into Active
Pharmaceutical Ingredients (APIs) and specialty chemicals. With robust
financial growth, a diversified portfolio, and an expanding global footprint,
Sigachi is now powering ahead as a vertically integrated pharmaceutical player.
In FY25, the company posted a 46.21% EBITDA growth and a 25.42% revenue
surge to ₹5,003 million, driven by excipient demand, API capacity expansions,
and strategic partnerships across 65+ countries. The company has delivered an
EBITDA margin of 22.38% and 14.09% PAT for the same period. The year continues
Sigachi’s impressive performance over the last five years, where it has tripled
core revenues, achieved 28% PAT CAGR, and maintained low debt and strong
operating margins.
“FY25 has been a transformative year for Sigachi,” said Mr. Amit Raj
Sinha, MD & CEO of Sigachi Industries. “We’ve built on our core strengths
in excipients, while laying a strong foundation for future-ready API and
specialty chemical capabilities. Our upcoming Orvakal facility marks the
beginning of a new chapter in vertical integration, scalability, and regulatory
alignment. It will anchor our next phase of growth and enhance our
responsiveness to evolving global customer requirements”
Strategic API Push: New Facility at Orvakal, Andhra Pradesh
Sigachi has received Terms of Reference (ToR) approval from the State
Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for a
cutting-edge Bulk Drugs and Specialty Chemicals facility in Orvakal, Kurnool
District.
- Spread over 25.09
acres in Guttapadu-Orvakal node
- Development starts
August 1, 2025, post EC process initiation from July 15, 2025
- Will bolster Sigachi’s
API pipeline for regulated and semi-regulated markets
- Enables faster
commercialisation, seamless tech transfers, and greater proximity to
regulatory jurisdictions
- Reinforces
India’s Make in India mission through sustainable,
export-ready infrastructure
Global MCC Leadership
“In every tablet we
consume, there's a silent yet essential enabler—MCC. And Sigachi is mastering
this art with unmatched precision. Our proprietary DAPOBAL®
process, in-house acid recovery, and 60+ MCC grades support customers ranging
from global generics to premium innovators. Our manufacturing capacity of 22,000 MTPA
(operating at over 80% utilisation) (metric tonnes per annum) makes us not just
India’s largest, but also among the Top 5 MCC manufacturers globally. All our
facilities are certified with USFDA, EDQM, EXCiPACT, ISO 9001, ISO 14001, and
ISO 45001, enabling global customers to meet the highest quality and compliance
standards”, said Mr. Sinha, explaining more about its MCC expertise and
strategy.
Sigachi’s dominance in MCC is rooted in its five world-class
manufacturing units in Hyderabad, Dahej, Jhagadia, Raichur, and Sultanpur, with
three facilities dedicated solely to MCC.
Sigachi’s MCC sets the global benchmark for:
- Particle Size SD: ≤ 5
microns
- Moisture Content: ≤ 4%
- Flowability (Hausner
Ratio): ≤ 1.20
- Tablet Hardness @10kN:
≥ 7.5 kp
- Disintegration Time:
< 40 sec
The result: faster compression, better flow, and cleaner disintegration—delivering
predictability and quality that formulators can rely on.
Innovation and Business Roadmap
Two DSIR-certified R&D centres in Hyderabad and Dahej fuel
Sigachi’s innovation, backed by 7 patents, 46 trademarks, and advanced QbD
development frameworks.
A new API & Analytical R&D Centre in Hyderabad, launching in Q1
FY26, will centralise formulation research, data science, and excipient
compatibility modelling.
Sigachi’s next frontier includes:
- Launch of
Croscarmellose Sodium (CCS) in 18 months
- Co-processed MCCs like
HiCel SMCC and HiCel MCG 591/611
- Entry into 3D printed
pharma and nutraceuticals
With capacity expansions adding 7,500 MTPA for excipients, new markets
in LATAM, ASEAN, and the Middle East, and O&M contracts contributing 10% to
revenue, Sigachi’s growth engine is well-oiled for a 25% CAGR through FY28.
With 98% ESG-compliant
vendors, 100% sustainable packaging, and social impact programmes reaching over
12,600 lives, Sigachi is also a sustainability champion in pharma
manufacturing.
About Sigachi
Industries Ltd
Sigachi Industries
Limited is a global player in the pharmaceutical industry dedicated to
pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates,
Excipients, vitamin-mineral blends, and Operations and Management (O&M)
services. The company's diverse product portfolio is manufactured in 5
multilocational facilities, viz. Telangana, Gujarat, and Karnataka. Aligned
with its ethos of customer centricity, Sigachi established subsidiaries in UAE
and USA to be closer to its clients and improve responsiveness. With a strong
focus on innovation, quality, and regulatory compliance, we leverage
cutting-edge technology and global expertise to develop high-value pharma, food
and nutrition solutions that enhance healthcare outcomes. Committed to
excellence, we continuously invest in Research and Development, ensuring the
highest standards of quality and safety. With 36 years of industry experience,
Sigachi is a trusted partner for pharmaceutical and nutraceutical companies
spread across 65+ countries. At Sigachi, we collaborate with healthcare
partners, regulatory bodies, and global stakeholders to expand access to
reliable, high-quality pharmaceutical ingredients.